| Patent application number | Description | Published |
|---|
| 20090124005 | Enhanced Expression and Stability Regions - Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells. | 05-14-2009 |
| 20090137416 | Isolating Cells Expressing Secreted Proteins - A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has a T cell receptor variable domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 05-28-2009 |
| 20090162901 | Inducible Eukaryotic Expression System - Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells. | 06-25-2009 |
| 20100233803 | Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A) | 09-16-2010 |
| 20100291626 | ENHANCED EXPRESSION AND STABILITY REGIONS - Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells. | 11-18-2010 |
| 20100304436 | Fucosylation-Deficient Cells - An isolated nucleic acid encoding an FX protein having a serine at position | 12-02-2010 |
| 20100316627 | Human antibodies to human IL-6 receptor - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 12-16-2010 |
| 20100316636 | Method of Treating Rheumatoid Arthritis with an IL-6R Antibody - The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof. | 12-16-2010 |
| 20110159015 | HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4 - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like. | 06-30-2011 |
| 20110165650 | Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A) | 07-07-2011 |
